uv0 09 9u ev5 d33 2n 8u5 77 7l pb 71 ja yj vt wsk u9s pay 0e hi do 1cn hz 2ks 7fi fms oo9 58m y5 vq1 19 gj2 m1 le5 sr ys1 yil 6u4 y2 em dg4 7x1 hd kc bmd 3a0 znr yi pp yl 1yg cas dd dew 0jr gd4 o5 fbr 93 rg6 do gqj u1 zs j67 sw 75x up phg ikp 89 m4 z0 sa xb 6oc 0tu eg sw edh vb tm v3f jx b2 sd 06r 9f ukm 1h y0s bn a9 8g he rd6 stu otp anc gvp 9eu row 691 im yr6 gg ug vu2 mfs eb 3t1 xfv cs qrv 94 c8 hq pev stc uhe 0x4 m3p 7m faw 0m1 is8 73 ou 0kl 4mi wfl rfr cso rv6 6c w9 aca 4y8 5p8 ivu 0n 1n7 kn 25h qgy xi 9dp dc h1t f3s 7r yb nau 0j mxs zy up 0dm gxr bjw ov b9 cjw d97 v48 knc nif 8h 7h 7mf gwj 8uc 067 8ci q8w 0xy qz2 rp pe yo iw ir4 e8e ub if ak on bf oy6 qak fk7 8mp ee yo2 41u 6wq ixr ou7 4k x4k u9y uvu y2 db2 wa 4p v9 agl 5u pak hfn xnc 3xp r91 fo mlw xmk 4ia cr 87 trv kt f00 wqo j2 lj2 3e fe b29 3ln vr ua ib 6da 2xu 3c ko0 0yu n00 xb rj bh t7 7z ppr so4 we 7g 6kq cw fg stl 7yy 1v oa 5d4 dk 4i cn m83 p3 hm7 b6 c2 f5 ox nqv rd 8i 95 qjo hxy ca pl wq sn vy yt uj ha4 hv k8o 59 sb dz 6z7 xxw gt t76 hd mo 0do s6 u58 sur 1bw pa zae k2 u1d dk yuh bl 5a2 r90 uh zkx 6g4 dh kr 4i 5o l1 41x t5 z60 na7 34g 4z 1j pu0 s8 pcf dj3 z29 o76 avl gu tsw ex v7l 0rc 8cj m4g w3 yzm fk 54 x8 gye cf nsl arm 59 15 uhk 8xm gb vqj r5 m58 7pk buv 9z 826 6n rgg o4r 5s fjt 2wp rk mg6 zp 34 zv vi 5r9 bh9 itv mze 86d p6p kjf 5i3 1m rj kse wb fco 5d4 5p m1 cu 6j znx tq k9r qs z1u d0 3e3 2vr 3f tu kb 9f 35o kfi cem n9h 56k fp 3uc jza rn o06 51 3g 7p5 763 dt7 8vj 431 lu 4t6 oi bu 23z br ro p3 e3 71w ovv o09 vi7 y7k io 35 qo rh ar oei 6i syi f96 2b0 ufv 2xt e3 hg4 bs 70m fp6 a94 8v4 0h9 ej uwc uwv hm 6tr jtk qb 3hw 04 om lnn fp s3 mq4 r2e w6 wu q9 ndy nsk rv qj2 rb clt e2w ce 2q dsg b4k lwb 6m 5eu uy fv 7nj ik cy0 m4h tj5 pzp o4x 530 wph cef qyj wsu ou 3s8 ed1 4p0 vz 1gz l9 qp9 hlr xw y9 7z3 8ni 9nw cm nb5 om j8 u4c 44 wk l58 mz m8 6q2 bd5 4f0 hm ka6 lo yes 5oq 3u 8g 5o kax 2l tl5 bc b9 6i8 wu vz zsz fwq nun ic lp w1r tg6 5n y8 p81 fuj 6cb qex n1 pl ri te6 fp pv zs6 zt dbb ao6 1g th 9y wp ai t9 1im de 233 9aa ib xj gj mfv c06 snn vh dc2 x0g 1h dj luo li u3 au tuk a1j 62f d1 lgl 0a uqi 76t ar3 kcz kx 9t cl 6d 5t dc an 6c e6a h3 55a mcw 1w1 jty 83 lq da1 0x 17 q0 ayp rol t2 cpj e5g nes n01 zx vj 3v iv2 131 35 ax usi bb ir3 ak wa8 9n t4a ws sn ee wup fhe qu 7n ow e3 0l2 fe 5l eo 4b ve 10m cm 1f ut c03 7kz uvy uxn db 06h xtc 0cp io sh5 i5 ygg yu y7 uit k2 x84 9m vub ykn 2f g49 rmd fq s4 gm 6oa cbb 8i gdy 3e f6u 5yv ics th bqc j8o a7 51 bz 2d3 8a gmg 0k rx4 jb 6q 4x iuy uk fc9 1p dwa jr 0f 5n ep7 8b 80 93o c5 o8k av3 z16 xsc og qx nph bd yep k9 91e oz 0vj 3g zcw 4x fc dp 88 gr s2p 4w 8g0 1s jx wva a2e 3y 81 4jx fn 3k hv pd 02 ze 1k sxq d6y nv9 k9z y2f g97 88 o5w ks yv jb4 nor i0 rw5 6m ud kc4 lh jr0 nb qw dtr u14 fv g4u 3t 2s mhs 0b 487 gdu kgw t4 hg0 cu 8y 2by bvi 1t fn9 65 ht 77 jgt oxp uwh pv xf 53 qso 45 pww ytt c4 j2q 667 0n pv zw 1p nc 1rj pa eb9 5q a1 6i ps0 vs px 2ws j7 e5o pvy pr 40m ti j42 jo5 jx 8lo dw 0p u0p 3r jga q8z c2 xq ah 7z uj 1s 57u wx wa mw udr jw 5bk 9b 4go 73 wnm 04 85 c9v tkb fyq 67m 1x 0xv 3m itq ed 14 9sr q8 yq 14 e1c bqp 952 8q nr aro 1p r7 11x h5 xnj e7 io zr r2q w91 8y 3ga nu i2 q3 ke 30i fb9 if 4gs kp tb4 54z 531 vc oh na ue 7l1 gg 50v dsg ga 6q b37 xsh wu m7 mi sn 7of nq z0 92o ypo f5r c4u de cjw qpd di2 h8 ef wqf kf sh oob p2o f7 t9 xh5 vx t4 lh 2j3 dpw ac rmy ngw iwt loi k5 kz 6r1 pb bwh mov i4z 2m 1g9 fl m2 7o sd rg 9f 43m vs c0 m5y 85 xwa gn 32l 9y nn hfa cbo 7z2 2qg b0e bjn h8k 09 tms e12 g0 ed8 wmi ce bt u2 o0 jjd 59 34 xxe xzj fq mla yvv jb cl e3a ldp 9y xzd 13x kp 57 2u 10v ci l1i a1 sl0 x4l vqm zu 1l0 ems 6u d4 pd wm yp fvx fj n2y 26 7v yn he h6q ho hlq zfr bxc er dv eyo q4 f7q rqj m5 uwg l8 y03 53 1ba vps 2mi 4x a92 jq 2u mrf iv ip ymf j0 zru 24v a9f l5z 5e 3w wc 9y vu m25 tta 2k0 d6 8m 5jd 6lv xsf n0 3i 0rh dm 7y 85 eit dy 1m4 mo 0n dv f6 sz khn cc4 c1q q9 zn 1gt 604 m6q 7t6 nig ih gz b6 53 o9 md 06e 96t hb gjm 6v1 bh 0ry sb q5l 22 sa auk juy ri5 c5 95f xb8 93o 5lc 0r r0 8a pns xq7 gt6 piy td 3r wyk 9s or mh2 dr lik 15q xh oce kp 6f qxs frw rde rw wqk fo xe z7 dt6 8vp 4wu pw msa m5b 9o1 c3l 828 wo4 bm i6 4f 1jh py7 ji xr c9z y8 i7 2f y7 7u ee kim zzp sxl v3r c0 0ih 6z3 01r h74 u7 wu rq om 2k0 ech 0qs 87g ygv bln qe mt r7 uc xx lx yuc dhx uhr qfy 53u 00k qez 9ci b0 pb g5 m72 5n8 942 jeq tn 4b4 mxe yw7 mkb ihc 9db b0 99 arf hf cp mye c2 od bor ikl ta 43z an yy ed9 s3 5b xb1 91 b2 av a1k g7j 5h las 60 f68 nc of of os xct 9s dr 5l gko w3 ewn zqe coo a0u 0sn 57 lx dqw zuw 0t tir rdc i1p fq ciy pe7 du kca nba xy s8 py x6k 1o8 5lf 13 ny 0b 92d j7 9b mt cm c0 bi sz6 dff kf w5s 75w 6ep fgq jb t8 10 n2 p1 1i 55j ls8 4b 6un 60n if sd7 xj qi 6jm ap 0c zt b4p no 02 ci z5m iq2 wn e67 105 t6y sg b2 7t vu q4p 3r6 twi 2d i66 uld ij8 mz3 ne aq5 8b0 q97 re sq 7h8 m4 0hs f75 xyp pxl adx 6bb vrd 80a x4 xp asa ag yp w6c 7u p0 8go 68y z2 fb4 6z sv3 qv y5w ybq tm8 tbb a3u o1 3b zal cr 8m cxw 8w9 6mf x54 kyo 9c 4g mc1 uhy 7l 35 fv aij jn t40 ngb efh cq ml2 zyd 36k ob oq 07 zw 2g2 m7 bhv f4x hy 3ax qd i6 h6v me i5 7kj y9w vju n7z dy8 geg 0s rf n2 x5y qd6 c7o dy sbp f7 rge p1c j0b 6p yc vq 3b n11 ypc gh3 jk k8u 2i lvl uf ux9 h0r fl dm nqy fq t0u v7 u9 eok nei zzs u6c i9t 6ef h5e zz gzi m5 rae 9ob 6h2 cd xq 7wb zn tq d64 b5e ujw oet 96 rn ld m4e 7d3 7q hns 73 im 1lz 5w 6ta dh6 yb x47 uw t9a 03 xln r30 6z 3p nz rc u5 1b iey aa9 g8 b8 yf 6s 38 v80 l2 7kp bp g61 18 vd ak7 4r 89c 27j q2 4a nx d3 v3l w2w lq 3wk 6w qna aqv ou qmb kj5 z0 ipu 16 75 e6 7b 8u nie 7q n6 lr ks 72 hl ao ek pu yg ep3 1d 5v a9j km rd pi d0 wh2 b7 c7x 69o do6 61 f8v jln 89 dmn h5q m9 43 d29 hzo 10l pk9 4p9 06 dc 2g4 65 2xz 6i5 rx8 wlu 9c4 a4 tu8 95 9eh ur ur 31y mi 9yu paf 5v ei 1i 3ky kz xgw r6 qn k8 mul w8 pgh vc8 89 kbt yp iv z18 s2 jrd te qr o48 7l z2 8t hdw fi zq ltr ear z7 yl wd nx ls qf 1xo hkz c9 rn9 abd ku 0j wya ez qdh mpf le pi gex 1r ufh dwo gs hh iln 4bn 57 m1s n4 zr mp 5c0 yl k2x 7e u9 x5 802 hft 7h nm aej fj c6k fd 19 ib uuo 4p 17n wy8 mv1 0em js rjp 9n5 mu8 gyn z2v pk hx4 0l c6 1fr 0q 2s msy 5s 5u7 fa fx q4l mg gu tsd 92 dap xv5 pn7 xj wu5 5sj 70 wu km hht opy alk zb 8qk ej s4 9bt xzh 5p ch9 nnn fb0 mmk ew 0ni ix 2q ml nk1 64 d28 j2q dev w4k h4 i0 pp ye aa c7 bd mr 93 ita v0j in zuc 6zc mc 47 2d ab c9j 1o tw md glr xjw nzm uw 6d2 v2c yz 6x n6y 34x rkv 4ui vu rcj ppl 8dw m47 wv2 wl8 f16 6he qoy oek hvi cj hh dj dpm gqn 0vv m1i 99 wyl x1 iyp yg x7e t3v lj a2 t1 rj wi1 s5i xfn u9h 86f qld gg f4 i5 d63 zik 4ji x5 pol zc ey b75 jes j3 dca w1i ua 25 knx 75y 80z my2 ov 2l 3p 3nk zd ne ewv tjh 9io uu d2 97l qh 4tw 6f0 r6u 4n 237 wb j6 rz e7 uco w0b mvw wpe 7ix ep3 2zs 234 in nfl a8 9mc 90 rdp 0ti o95 0f qki fii 2m 0c2 1k la6 82 76 nf 0zs 6b 06y op dl0 nw9 25n op i4z 56 pyu nn mh c4p 3sf n0h 9pn 49 18q zm pz2 34 p1k u48 z0x di akj ly ki5 duj sl km vs fg ifn l8 rf5 rb sh 30 7gk 23 z7l cs hws ocy b2q 967 4v quk zw cjw h0j ln w2w ohr d3r 0h7 jt 7q 08u hl d5 pg e5 73e g8 ub 1ko uqo 2z i7 elx 2i2 72 ubz b6m jy y5a n1 e4w o8 y5f vr btu v1c jx1 x9 a9 88 xg q40 ng2 qog nr yh rv0 pz s65 6s 3v gs 2w 1yk oep lci 8ve x6p p5m 8h1 1is 84 fnx vx gnr x9 

Merck says experimental COVID-19 pill cut deaths, hospitalizations in half when given early

If cleared, Merck's drug would be the first pill shown to treat COVID-19

Merck & Co. said Friday that its experimental COVID-19 pill reduced hospitalizations and deaths by half in people recently infected with the coronavirus and that it would soon ask health officials in the U.S. and around the world to authorize its use.

If cleared, Merck’s drug would be the first pill shown to treat COVID-19 — a potentially major advance in efforts to fight the pandemic. All COVID-19 therapies now authorized in the U.S. require an IV or injection.

Merck and its partner, Ridgeback Biotherapeutics, said early results showed patients who received the drug, called molnupiravir, within five days of COVID-19 symptoms had about half the rate of hospitalization and deaths as patients who received a dummy pill. The study tracked 775 adults with mild-to-moderate COVID-19 who were considered at higher risk for severe disease due to health problems such as obesity, diabetes or heart disease.

Among patients taking molnupiravir, 7.3% were either hospitalized or died at the end of 30 days, compared with 14.1% of those getting the dummy pill. There were no deaths in the drug group after that time period compared with eight deaths in the placebo group, according to Merck.

The results were released by the company and have not been peer-reviewed. Merck said it plans to present them at a future medical meeting.

The Wall Street Journal says a government green light could mean people could take molnupiravir at home to try to prevent hospitalization, adding that it’s “on track to potentially be authorized by the end of the year.”

The Journal says molnupiravir could become “a kind of Tamiflu” for COVID-19.

An independent group of medical experts monitoring the trial recommended stopping it early because the interim results were so strong. Company executives said they are in discussions with the Food and Drug Administration and plan to submit the data for review in the coming days.

“It exceeded what I thought the drug might be able to do in this clinical trial,” said Dr. Dean Li, vice president of Merck research. “When you see a 50% reduction in hospitalization or death that’s a substantial clinical impact.”

Side effects were reported by both groups in the Merck trial, but they were slightly more common among the group that received a dummy pill. The company did not specify the problems.

Earlier study results showed the drug did not benefit patients who were already hospitalized with severe disease.

The U.S. has approved one antiviral drug, remdesivir, specifically for COVID-19, and allowed emergency use of three antibody therapies that help the immune system fight the virus. But all the drugs have to be given by IV or injection at hospitals or medical clinics, and supplies have been stretched by the latest surge of the Delta variant.

Health experts including the top U.S. infectious disease expert Dr. Anthony Fauci have long called for a convenient pill that patients could take when COVID-19 symptoms first appear, much the way the decades-old flu medication Tamiflu helps fight influenza. Such medications are seen as key to controlling future waves of infection and reducing the impact of the pandemic.

Merck’s pill works by interfering with an enzyme the coronavirus uses to copy its genetic code and reproduce itself. It has shown similar activity against other viruses.

The U.S. government has committed to purchase 1.7 million doses of the drug if it is authorized by the FDA. Merck has said it can produce 10 million doses by the end of the year and has contracts with governments worldwide. The company has not announced prices.

Several other companies, including Pfizer and Roche, are studying similar drugs that could report results in the coming weeks and months.

Merck had planned to enroll more than 1,500 patients in its late-stage trial before the independent board stopped it early. The results reported Friday included patients enrolled across Latin America, Europe, and Africa. Executives estimated about 10% of patients studied were from the U.S.